

## UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Offic

Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

FILING DATE FIRST NAMED INVENTOR ATTORNEY DOCKET NO. APPLICATION NO. <u>076787011003</u> CHAPPELL 02/28/00 09/514,513 **EXAMINER** HM22/0228 NELSON, A Paul T Clark Clark & Elbing LLP ART UNIT PAPER NUMBER 176 Federal Street 1638 Boston MA 02110 02/28/01 DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

**Commissioner of Patents and Trademarks** 





### UNITED STATES DEPARTMENT OF COMMERCE Pat nt and Trademark Office

COMMISSIONER OF PATENTS AND TRADEMARKS

Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	FIRST NAMED APP	PLICANT	ATTORNEY DOCKET NO.
٢		٦		
				EXAMINER
		<u> </u>		EXAMINEN
		Γ		
		<u></u>	ART UNIT	PAPER NUMBER
				3
L . ·		-J		
			DATE MAILEI	D:

Please find below a communication from the EXAMINER in charge of this application.

#### Commissioner of Patents

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.

Applicant is given ONE MONTH, or THIRTY DAYS, whichever is longer, from the date of this letter within which to comply with the sequence rules, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a). In no case may an applicant extend the period for response beyond the SIX MONTH statutory period. Direct the response to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the response.

2. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Amy J. Nelson whose telephone number is (703) 306-3218. The examiner can normally be reached on Monday-Friday from 8:00 AM - 4:30 PM.

If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's supervisor, Paula Hutzell, can be reached at (703) 308-4310. The fax phone number for this Group is (703) 308-4242 or (703) 305-3014.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-1234.

AMY J. NELSON, PH.D PRIMARY EXAMINER

Amy J. Nelson

February 27, 2001

Application No.: 09/514,513

### NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

,	
1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.	•
2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).	
3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required b 37 C.F.R. 1.821(e).	у
4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."	
5. The computer readable form that has been filed with this application has been found to be damag and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).	ed
6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).	
7. Other:	
Applicant Must Provide:	
An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".	
An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its e into the specification.	ntry
A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).	
For questions regarding compliance to these requirements, please contact:	
For Rules Interpretation, call (703) 308-4216 For CRF Submission Help, call (703) 308-4212 Patentln Software Program Support (SIRA) Technical Assistance	
To Purchase PatentIn Software703-306-2600	

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE

# NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE NEOR AMINO ACID SEQUEN DECLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

	<ol> <li>This application clearly falls to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.</li> </ol>
	2. This application does not contain, as a separate part of the disclosure on paper copy, a *Sequence Listing* as required by 37 C.F.R. 1.821(c).
	3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
1	4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
£.,	5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
•	6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
	7. Other: Applicant should follow the format of the attached sample statement to request that the CRF filed in the parent application be used to create a CRF in this application.
	Applicant Must Provide:
	An Initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
	An <u>Initial</u> or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
	A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).
	For questions regarding compliance to these requirements, please contact:  For Rules Interpretation, call (703) 308-4216  For CRF Submission Help, call (703) 308-4212  For Patentin software help, call (703) 308-6856  PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE
	The second of th

		Anares of A	Address: COMMISSIONER OF PATENTS AND WASHINGTON, D.C. 20231			
SERIAL NUMBER	FILING DATE	••	FIRST NAMED APPLICANT		ATTORNEY DOCKET NO.	
1 .			' [	EXAMI	NER	
				ART UNIT	PAPER NUMBER	

Please find below a communication from the EXAMINER in charge of this application.

**Commissioner of Patents** 

DATE MAILED:

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid

APPLICANT IS GIVEN ONE EXTENDIBLE MONTH FROM THE DATE OF THIS LETTER WITHIN WHICH TO Sequence Disclosures. COMPLY WITH THE SEQUENCE RULES, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136. In no case may an applicant xtend the period for response beyond the six month statutory period. Direct the response to the undersign d. Applicant is requested to return a copy of the attached Notice to Comply with the response.

Any inquiry concerning this communication or earlier communications from the examiner should be whose telephone number is (703) 30 directed to

Address: COMMISSIVING --Washington, D.C. 20231 ATTORNEY DOCKET NO. FIRST NAMED APPLICANT FILING DATE SERIAL NUMBER ١ **EXAMINER** PAPER NUMBER ART UNIT

DATE MAILED:

Please find below a communication from the EXAMINER in charge of this application.

**Commissioner of Patents** 

This application contains sequence disclosures that are encompassed by the definitions for nucleotid and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid

APPLICANT IS GIVEN ONE EXTENDIBLE MONTH FROM THE DATE OF THIS LETTER WITHIN WHICH TO Sequence Disclosures. COMPLY WITH THE SEQUENCE RULES, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136. In no case may an applicant xtend the period for response beyond the six month statutory period. Direct the response to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the response.

Any inquiry concerning this communication or earlier communications from the examiner should be whose telephone number is (703) 30 directed to

## Sample Statement

Sample Request to Use Computer Readable orm from Another Application

The following paragraph, or language having the same effect, can be used to invoke the procedures of 37 CFR section 1.821(e) in which an identical computer readable form from another application is used in a given application. The paragraph should be incorporated into a separate paper to be submitted in the given application:

The computer readable form in this application, 08/100,000, is identical with that filed Application Number 07/999,999, filed March 1, 1988. In accordance with 37 CFR 1.821(e), please use the [first-filed, last-filed or only, whichever is applicable] computer readable form filed in that application as the computer readable form for the instant application. It is understood that the Patent and Trademark Office will make the necessary change in application number and filing date for the computer readable form that will be used for the instant application. A paper copy of the Sequence Listing is (included in the originallyfiled specification of the instant application, included in a separately filed preliminary amendment for incorporation into the specification, whichever is applicable].

# NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCES DIOR AMINO ACID SEQUENCES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

	1.7	This application clearly falls to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
		2. This application does not contain, as a separate part of the disclosure on paper copy, a *Sequence Listing* as required by 37 C.F.R. 1.821(c).
		3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
,		4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
€.		5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
•		6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
	X	7. Other: Applicant should follow the format of the attached sample statement to request that the CRF filed in the parent application be used to create a CRF in this application.
	Αp	plicant Must Provide:
		An Initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
	Ü	An <u>initial</u> or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
		A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(d).
	Fo	or questions regarding compliance to these requirements, please contact:
	FO	or Rules Interpretation, call (703) 308-4216
	Fo	or CRF Submission Help, call (703) 308-4212 or Patentin software help, call (703) 308-6856
		PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE
		THE TOUR RESPONSE